LU91348I2 - Telbivudine et ses sels pharmaceutiquement acceptables - Google Patents

Telbivudine et ses sels pharmaceutiquement acceptables

Info

Publication number: LU91348I2
Authority: LU; Luxembourg
Prior art keywords: pentofuranonucleoside; deoxy; pharmaceutically acceptable; erythro; prodrug
Prior art date: 1998-08-10

Application number

LU91348C

Other languages

English (en)

Other versions

LU91348I9 (fr

Original Assignee

Idenix Cayman Ltd C7O Walkers

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-10

Filing date

2007-07-18

Publication date

2007-09-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26791121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91348(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-07-18 Application filed by Idenix Cayman Ltd C7O Walkers, Centre Nat Rech Scient filed Critical Idenix Cayman Ltd C7O Walkers

2007-09-18 Publication of LU91348I2 publication Critical patent/LU91348I2/fr

2018-12-31 Publication of LU91348I9 publication Critical patent/LU91348I9/fr

Links

150000003839 salts Chemical class 0.000 title abstract 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 title 1
IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 title 1
229960005311 telbivudine Drugs 0.000 title 1
208000002672 hepatitis B Diseases 0.000 abstract 2
229940002612 prodrug Drugs 0.000 abstract 2
239000000651 prodrug Substances 0.000 abstract 2
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
125000005140 aralkylsulfonyl group Chemical group 0.000 abstract 1
125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000001177 diphosphate Substances 0.000 abstract 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract 1
235000011180 diphosphates Nutrition 0.000 abstract 1
150000004712 monophosphates Chemical class 0.000 abstract 1
150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 1
IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 abstract 1
239000001226 triphosphate Substances 0.000 abstract 1
235000011178 triphosphate Nutrition 0.000 abstract 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

LU91348C 1998-08-10 2007-07-18 Telbivudine et ses sels pharmaceutiquement acceptables LU91348I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9611098P	1998-08-10	1998-08-10
US13135299P	1999-04-28	1999-04-28
PCT/US1999/018149 WO2000009531A2 (fr)	1998-08-10	1999-08-10	β-L-2'-DESOXY-NUCLEOSIDES POUR LE TRAITEMENT DE L'HEPATITE B

Publications (2)

Publication Number	Publication Date
LU91348I2 true LU91348I2 (fr)	2007-09-18
LU91348I9 LU91348I9 (fr)	2018-12-31

Family

ID=26791121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91348C LU91348I2 (fr)	1998-08-10	2007-07-18	Telbivudine et ses sels pharmaceutiquement acceptables

Country Status (21)

Country	Link
US (5)	US6395716B1 (fr)
EP (2)	EP2415776B1 (fr)
JP (2)	JP4294870B2 (fr)
KR (4)	KR100702230B1 (fr)
CN (3)	CN1257912C (fr)
AT (1)	ATE313550T1 (fr)
AU (1)	AU5475799A (fr)
BR (1)	BRPI9912896B8 (fr)
CA (1)	CA2340156C (fr)
CY (2)	CY2007017I1 (fr)
DE (2)	DE69929060T2 (fr)
DK (3)	DK1431304T3 (fr)
ES (3)	ES2579903T3 (fr)
FR (1)	FR07C0046I2 (fr)
LU (1)	LU91348I2 (fr)
MX (1)	MXPA01001507A (fr)
NL (1)	NL300286I2 (fr)
PT (2)	PT2415776T (fr)
RU (1)	RU2424016C2 (fr)
SG (1)	SG132498A1 (fr)
WO (1)	WO2000009531A2 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT831852E (pt) *	1995-06-07	2007-02-28	Uab Research Foundation	Nucleósidos com actividade anti-vírus da hepatite b
PT2415776T (pt) *	1998-08-10	2016-07-07	Novartis Ag	Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
US6444652B1 (en) *	1998-08-10	2002-09-03	Novirio Pharmaceuticals Limited	β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
WO2001034618A2 (fr) *	1999-11-12	2001-05-17	Pharmasset Limited	Synthese de 2'-deoxy-l-nucleosides
EP1600452A3 (fr)	1999-11-12	2008-09-10	Pharmasset, Inc.	Synthèse de 2'-déoxy-L-nucléosides
WO2001064221A1 (fr) *	2000-02-29	2001-09-07	Bristol-Myers Squibb Co.	Formulation d'entecavir a faible dose et utilisation
WO2001067772A2 (fr) *	2000-03-09	2001-09-13	Videoshare, Inc.	Partage d'une sequence video
US6822089B1 (en) *	2000-03-29	2004-11-23	Isis Pharmaceuticals, Inc.	Preparation of deoxynucleosides
EP1964569A3 (fr) *	2000-04-13	2009-07-22	Pharmasset, Inc.	Dérivés de nucléoside substitué 3'-Or 2'-hydroxymethyl pour le traitement des infections virales
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
US6787526B1 (en) *	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
EP1736478B1 (fr) *	2000-05-26	2015-07-22	IDENIX Pharmaceuticals, Inc.	Procédés et compositions de traitement des flavivirus et des pestivirus
EA005890B1 (ru)	2000-05-26	2005-06-30	Айденикс (Кайман) Лимитед	СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
MY141594A (en) *	2000-06-15	2010-05-14	Novirio Pharmaceuticals Ltd	3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6875751B2 (en) *	2000-06-15	2005-04-05	Idenix Pharmaceuticals, Inc.	3′-prodrugs of 2′-deoxy-β-L-nucleosides
DE60144573D1 (de)	2000-11-29	2011-06-16	Mitsui Chemicals Inc	Verfahren und Zwischenprodukte bei der Synthese von L-Thymidin
CN101250208B (zh) *	2000-11-29	2012-06-20	三井化学株式会社	L-核酸衍生物及其合成方法
CA2470938A1 (fr)	2001-12-20	2003-07-03	Beth Israel Deaconess Medical Center	Traitement du virus d'epstein-barr, infection a l'herpesvirus lie au sarcome de kaposi et proliferation cellulaire anormale associee
AU2002364216A1 (en) *	2001-12-21	2003-07-15	Micrologix Biotech Inc.	Anti-viral 7-deaza l-nucleosides
WO2003072757A2 (fr) *	2002-02-28	2003-09-04	Biota, Inc.	Mimetiques nucleotidiques et leurs promedicaments
CN1302779C (zh) *	2002-06-27	2007-03-07	美迪维尔公司	含有阿巴卡韦和阿洛夫定的药物制剂及其用途
PL374792A1 (en)	2002-06-28	2005-10-31	Idenix (Cayman) Limited	2' and 3'-nucleoside prodrugs for treating flaviviridae infections
US7608600B2 (en)	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TW200500375A (en)	2002-06-28	2005-01-01	Idenix Cayman Ltd	Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
CN1678326A (zh) *	2002-06-28	2005-10-05	埃迪尼克斯(开曼)有限公司	用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
NZ537662A (en) *	2002-06-28	2007-10-26	Idenix Cayman Ltd	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI244393B (en)	2002-08-06	2005-12-01	Idenix Pharmaceuticals Inc	Crystalline and amorphous forms of beta-L-2'-deoxythymidine
EP1572095B1 (fr)	2002-09-13	2015-06-10	Novartis AG	Beta-l-2'-desoxynucleosides pour l'utilisation dans le traitement de souches du vhb resistantes
BR0315795A (pt) *	2002-10-31	2005-09-13	Metabasis Therapeutics Inc	Pró-medicamentos de monofosfato de citarabina
LT1576138T (lt)	2002-11-15	2017-06-26	Idenix Pharmaceuticals Llc	2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003300901A1 (en) *	2002-12-12	2004-06-30	Idenix (Cayman) Limited	Process for the production of 2'-branched nucleosides
WO2004084453A2 (fr)	2003-03-20	2004-09-30	Microbiologica Quimica E Farmaceutica Ltd.	Procedes de fabrication de 2'-desoxy-$g(b)-l-nucleosides
KR20060015542A (ko)	2003-04-28	2006-02-17	이데닉스 (케이만) 리미티드	산업 규모의 뉴클레오시드 합성
WO2004096197A2 (fr) *	2003-05-02	2004-11-11	Universita Degli Studi Di Cagliari	5-aza-7-deazapurine nucleosides pour le traitement de flaviviridae
HUE029877T2 (en)	2003-05-30	2017-04-28	Gilead Pharmasset Llc	Modified fluorinated nucleoside analogues
WO2005003374A2 (fr) *	2003-06-30	2005-01-13	Idenix (Cayman) Limited	Synthese de nucleosides ?-l-2-desoxy
CN1315863C (zh) *	2003-12-12	2007-05-16	河南省科学院质量检验与分析测试研究中心	β－L－2'－脱氧－核苷衍生物、其合成方法及其药物用途
CN101023094B (zh)	2004-07-21	2011-05-18	法莫赛特股份有限公司	烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US8492539B2 (en)	2004-09-14	2013-07-23	Gilead Pharmasset Llc	Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) *	2005-03-11	2010-08-04	株式会社ケンウッド	音声合成装置、音声合成方法及びプログラム
US8076303B2 (en)	2005-12-13	2011-12-13	Spring Bank Pharmaceuticals, Inc.	Nucleotide and oligonucleotide prodrugs
ES2422290T3 (es) *	2005-12-23	2013-09-10	Idenix Pharmaceuticals Inc	Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
EP2007789B1 (fr)	2006-04-11	2015-05-20	Novartis AG	Inhibiteurs spirocycliques du VIH/du virus de l'hépatite C
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US20090082306A1 (en) *	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched telbivudine
TW200946541A (en)	2008-03-27	2009-11-16	Idenix Pharmaceuticals Inc	Solid forms of an anti-HIV phosphoindole compound
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
PA8855601A1 (es)	2008-12-23	2010-07-27		Forformidatos de nucleósidos
NZ593649A (en)	2008-12-23	2013-11-29	Gilead Pharmasset Llc	Nucleoside analogs
US20110182850A1 (en)	2009-04-10	2011-07-28	Trixi Brandl	Organic compounds and their uses
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
TWI583692B (zh)	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
KR101961601B1 (ko) *	2009-11-16	2019-03-25	유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드	바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
SG184324A1 (en)	2010-03-31	2012-11-29	Gilead Pharmasset Llc	Nucleoside phosphoramidates
JP5909495B2 (ja)	2010-10-08	2016-04-26	ノバルティスアーゲー	スルファミドｎｓ３阻害剤のビタミンｅ製剤
CA2818853A1 (fr)	2010-11-30	2012-06-07	Gilead Pharmasset Llc	2'-spirocyclo-nucleosides destines a la therapie contre le virus de l'hepatite c et le virus de la dengue
CN102649788B (zh) *	2011-02-28	2015-03-25	四川大学	β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途
EP2709613B2 (fr)	2011-09-16	2020-08-12	Gilead Pharmasset LLC	Procédés permettant de traiter le virus de l'hépatite c (hcv)
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
EP2950786B1 (fr)	2013-01-31	2019-11-27	Gilead Pharmasset LLC	Formulation de combinaison de deux composés antiviraux
PT3038601T (pt)	2013-08-27	2020-06-30	Gilead Pharmasset Llc	Formulação combinada de dois compostos antivirais
AU2015217221A1 (en)	2014-02-13	2016-08-11	Ligand Pharmaceuticals, Inc.	Prodrug compounds and their uses
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
CA3087932A1 (fr)	2018-01-09	2019-07-18	Ligand Pharmaceuticals, Inc.	Composes acetal et leurs utilisations therapeutiques
CN110680806A (zh) *	2018-07-04	2020-01-14	郑州泰丰制药有限公司	一种替比夫定颗粒的制备方法
CN108570078A (zh) *	2018-07-18	2018-09-25	荆门医药工业技术研究院	一种制备1-O-乙酰基-2,3,5-三-O-苯甲酰基-β-D-呋喃核糖的方法
CN114133398B (zh) *	2021-12-31	2022-11-22	中南民族大学	氨基酸取代的阿昔洛韦类三环核苷衍生物及其合成方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB875971A (en)	1959-01-14	1961-08-30	Hoffmann La Roche	A process for the manufacture of uridine and thymidine derivatives and novel compounds concerned therein
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5223263A (en)	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
US4916122A (en)	1987-01-28	1990-04-10	University Of Georgia Research Foundation, Inc.	3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en)	1987-01-28	1993-03-02	University Of Georgia Research Foundation, Inc.	3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
GB8719367D0 (en)	1987-08-15	1987-09-23	Wellcome Found	Therapeutic compounds
EP0380558A4 (en)	1987-09-22	1991-07-31	The Regents Of The University Of California	Liposomal nucleoside analogues for treating aids
US6020322A (en)	1993-11-09	2000-02-01	Pro-Neuron, Inc.	Acyl deoxyribonucleoside derivatives and uses thereof
EP0712629B1 (fr)	1987-10-28	2003-06-18	Wellstat Therapeutics Corporation	Dérivés acylés de déoxyribonucléoside et leurs utilisations
JP2675864B2 (ja)	1988-07-05	1997-11-12	キヤノン株式会社	被記録材及びこれを用いたインクジェット記録方法
SE8802687D0 (sv)	1988-07-20	1988-07-20	Astra Ab	Nucleoside derivatives
US5194654A (en)	1989-11-22	1993-03-16	Vical, Inc.	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en)	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en)	1989-11-22	1995-10-31	Vestar, Inc.	Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en)	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
WO1991016920A1 (fr)	1990-05-07	1991-11-14	Vical, Inc.	Promedicaments lipidiques au salicylate et medicaments anti-inflammatoires non steroidiens
JPH05507279A (ja)	1990-05-29	1993-10-21	ネクススター・ファーマシューティカルズ・インコーポレイテッド	グリセロールジ―およびトリホスフェート誘導体の合成
EP0533833B1 (fr)	1990-06-13	1995-12-20	GLAZIER, Arnold	Promedicaments phosphoreux
ATE133233T1 (de)	1990-07-12	1996-02-15	G Drill Ab	Gesteinsbohrgerät mit hydraulischem antrieb im bohrloch
EP0481214B1 (fr) *	1990-09-14	1998-06-24	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Pro-médicaments dérivés de phosphonates
US5206244A (en) *	1990-10-18	1993-04-27	E. R. Squibb & Sons, Inc.	Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
US5256641A (en)	1990-11-01	1993-10-26	State Of Oregon	Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization	Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en)	1990-11-01	1992-09-22	State Of Oregon	Covalent lipid-drug conjugates for drug targeting
US5543390A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
IT1246983B (it)	1990-11-13	1994-12-12	Consiglio Nazionale Ricerche	L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
IL100502A (en)	1991-01-03	1995-12-08	Iaf Biochem Int	PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
KR100270806B1 (ko)	1991-03-06	2000-11-01	템블 존 엘	5-플루오로-2`-데옥시-3`-티아시티딘을 함유하는 b형 간염 치료를 위한 약제
US5220003A (en) *	1991-03-29	1993-06-15	The Regents Of The University Of California	Process for the synthesis of 2',3'-dideoxynucleosides
WO1992018517A1 (fr)	1991-04-17	1992-10-29	Yale University	Procede de traitement ou de prevention du virus de l'hepatite b
AU668873B2 (en)	1991-07-12	1996-05-23	Chimerix, Inc.	Antiviral liponucleosides: treatment of hepatitis B
US5554728A (en)	1991-07-23	1996-09-10	Nexstar Pharmaceuticals, Inc.	Lipid conjugates of therapeutic peptides and protease inhibitors
JPH08512019A (ja) *	1993-03-10	1996-12-17	ザ・ウエルカム・ファウンデーション・リミテッド	免疫反応剤およびキレート化された放射性核種からなるｌ−エナンチオメリックオリゴヌクレオチド複合体を用いる腫瘍ターゲッティング
GB9307043D0 (en) *	1993-04-05	1993-05-26	Norsk Hydro As	Chemical compounds
JP3693357B2 (ja)	1993-04-09	2005-09-07	峯郎実吉	逆転写酵素阻害剤
WO1994026273A1 (fr)	1993-05-12	1994-11-24	Hostetler Karl Y	Derives d'acyclovir a usage topique
US5627160A (en) *	1993-05-25	1997-05-06	Yale University	L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
CA2171550C (fr) *	1993-09-10	2008-08-26	Raymond F. Schinazi	Nucleosides avec activite virale anti-hepatite b
US5587362A (en)	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
WO1996011204A1 (fr) *	1994-10-07	1996-04-18	Max-Delbrück-Centrum für Molekulare Medizin	NOUVEAUX β-L-NUCLEOSIDES ET LEUR UTILISATION
US5559101A (en) *	1994-10-24	1996-09-24	Genencor International, Inc.	L-ribofuranosyl nucleosides
US5696277A (en)	1994-11-15	1997-12-09	Karl Y. Hostetler	Antiviral prodrugs
PT831852E (pt)	1995-06-07	2007-02-28	Uab Research Foundation	Nucleósidos com actividade anti-vírus da hepatite b
US6025335A (en) *	1995-09-21	2000-02-15	Lipitek International, Inc.	L-Nucleoside Dimer Compounds and therapeutic uses
EP1069903A1 (fr)	1998-03-11	2001-01-24	Lipitek International, Inc.	Nouveaux analogues de nucleosides et leurs utilisations dans le traitement de maladies
CA2335617C (fr)	1998-06-24	2009-12-15	Novirio Pharmaceuticals Limited	3'-azido-2',3'-dideoxyuridine (cs-87) utilise en combinaison avec d'autres medicaments anti-vih pour la fabrication d'un medicament destine a traiter le vih
US6444652B1 (en) *	1998-08-10	2002-09-03	Novirio Pharmaceuticals Limited	β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
PT2415776T (pt) *	1998-08-10	2016-07-07	Novartis Ag	Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
MY164523A (en) *	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
EA005890B1 (ru) *	2000-05-26	2005-06-30	Айденикс (Кайман) Лимитед	СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
EP1736478B1 (fr) *	2000-05-26	2015-07-22	IDENIX Pharmaceuticals, Inc.	Procédés et compositions de traitement des flavivirus et des pestivirus
US6787526B1 (en) *	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides

1999
- 1999-08-10 PT PT101846574T patent/PT2415776T/pt unknown
- 1999-08-10 KR KR1020067007304A patent/KR100702230B1/ko not_active Expired - Lifetime
- 1999-08-10 MX MXPA01001507A patent/MXPA01001507A/es active IP Right Grant
- 1999-08-10 PT PT4075926T patent/PT1431304E/pt unknown
- 1999-08-10 JP JP2000564981A patent/JP4294870B2/ja not_active Expired - Lifetime
- 1999-08-10 EP EP10184657.4A patent/EP2415776B1/fr not_active Expired - Lifetime
- 1999-08-10 US US09/371,747 patent/US6395716B1/en not_active Expired - Lifetime
- 1999-08-10 EP EP99941027A patent/EP1104436B1/fr not_active Expired - Lifetime
- 1999-08-10 DE DE69929060T patent/DE69929060T2/de not_active Expired - Lifetime
- 1999-08-10 SG SG200302078-1A patent/SG132498A1/en unknown
- 1999-08-10 CA CA002340156A patent/CA2340156C/fr not_active Expired - Lifetime
- 1999-08-10 DK DK04075926T patent/DK1431304T3/en active
- 1999-08-10 CN CNB998095532A patent/CN1257912C/zh not_active Expired - Lifetime
- 1999-08-10 WO PCT/US1999/018149 patent/WO2000009531A2/fr not_active Ceased
- 1999-08-10 RU RU2006147216/04A patent/RU2424016C2/ru active Protection Beyond IP Right Term
- 1999-08-10 ES ES10184657.4T patent/ES2579903T3/es not_active Expired - Lifetime
- 1999-08-10 BR BRPI9912896A patent/BRPI9912896B8/pt not_active IP Right Cessation
- 1999-08-10 KR KR1020067007301A patent/KR100691737B1/ko not_active Expired - Lifetime
- 1999-08-10 DE DE200712000062 patent/DE122007000062I1/de active Pending
- 1999-08-10 DK DK99941027T patent/DK1104436T3/da active
- 1999-08-10 KR KR1020057009515A patent/KR100568035B1/ko not_active Expired - Lifetime
- 1999-08-10 AU AU54757/99A patent/AU5475799A/en not_active Abandoned
- 1999-08-10 CN CNB2004100028639A patent/CN100387237C/zh not_active Expired - Lifetime
- 1999-08-10 KR KR1020017001758A patent/KR100634342B1/ko not_active Expired - Lifetime
- 1999-08-10 CN CNB021265739A patent/CN100482236C/zh not_active Expired - Lifetime
- 1999-08-10 ES ES04075926.8T patent/ES2531928T3/es not_active Expired - Lifetime
- 1999-08-10 ES ES99941027T patent/ES2255295T3/es not_active Expired - Lifetime
- 1999-08-10 DK DK10184657.4T patent/DK2415776T3/en active
- 1999-08-10 AT AT99941027T patent/ATE313550T1/de active
2001
- 2001-12-14 US US10/022,276 patent/US6569837B1/en not_active Expired - Lifetime
2003
- 2003-05-13 US US10/438,167 patent/US20030225028A1/en not_active Abandoned
2005
- 2005-09-22 US US11/232,818 patent/US7304043B2/en not_active Expired - Lifetime
2007
- 2007-05-07 JP JP2007122896A patent/JP2007269798A/ja active Pending
- 2007-07-18 LU LU91348C patent/LU91348I2/fr unknown
- 2007-08-06 CY CY200700017C patent/CY2007017I1/el unknown
- 2007-08-09 NL NL300286C patent/NL300286I2/nl unknown
- 2007-09-21 FR FR07C0046C patent/FR07C0046I2/fr active Active
- 2007-10-30 US US11/929,807 patent/US20080064655A1/en not_active Abandoned
2015
- 2015-03-02 CY CY20151100218T patent/CY1116988T1/el unknown

Also Published As

Publication number	Publication date
RU2006147216A (ru)	2008-07-10
CY2007017I2 (el)	2009-11-04
EP1104436B1 (fr)	2005-12-21
LU91348I9 (fr)	2018-12-31
CN100482236C (zh)	2009-04-29
ES2255295T3 (es)	2006-06-16
CN1257912C (zh)	2006-05-31
PT1431304E (pt)	2015-03-09
HK1097776A1 (en)	2007-07-06
CN100387237C (zh)	2008-05-14
KR20050062664A (ko)	2005-06-23
PT2415776T (pt)	2016-07-07
CY2007017I1 (el)	2009-11-04
WO2000009531A3 (fr)	2000-06-15
DE69929060T2 (de)	2006-08-31
US20030225028A1 (en)	2003-12-04
US6569837B1 (en)	2003-05-27
KR100634342B1 (ko)	2006-10-16
US6395716B1 (en)	2002-05-28
NL300286I1 (nl)	2007-10-01
DK1431304T3 (en)	2015-03-02
JP2002522552A (ja)	2002-07-23
CY1116988T1 (el)	2017-04-05
EP1104436A2 (fr)	2001-06-06
US20080064655A1 (en)	2008-03-13
RU2424016C2 (ru)	2011-07-20
CN1478483A (zh)	2004-03-03
CN1320128A (zh)	2001-10-31
SG132498A1 (en)	2007-06-28
EP2415776B1 (fr)	2016-05-25
DK1104436T3 (da)	2006-04-03
DE69929060D1 (de)	2006-01-26
JP4294870B2 (ja)	2009-07-15
JP2007269798A (ja)	2007-10-18
HK1034083A1 (en)	2001-10-12
BR9912896A (pt)	2002-02-13
ATE313550T1 (de)	2006-01-15
KR20010072392A (ko)	2001-07-31
HK1111913A1 (en)	2008-08-22
CN1606983A (zh)	2005-04-20
US7304043B2 (en)	2007-12-04
US20060084624A1 (en)	2006-04-20
DE122007000062I1 (de)	2007-12-20
KR100691737B1 (ko)	2007-03-12
WO2000009531A2 (fr)	2000-02-24
KR20060035817A (ko)	2006-04-26
FR07C0046I2 (fr)	2008-05-09
KR100702230B1 (ko)	2007-04-03
AU5475799A (en)	2000-03-06
BRPI9912896B1 (pt)	2016-08-09
KR100568035B1 (ko)	2006-04-07
MXPA01001507A (es)	2003-09-10
FR07C0046I1 (fr)	2007-10-26
EP2415776A1 (fr)	2012-02-08
ES2579903T3 (es)	2016-08-17
NL300286I2 (nl)	2008-01-02
CA2340156C (fr)	2007-10-23
KR20060038483A (ko)	2006-05-03
CA2340156A1 (fr)	2000-02-24
DK2415776T3 (en)	2016-07-04
BRPI9912896B8 (pt)	2021-05-25
ES2531928T3 (es)	2015-03-20

Publication	Publication Date	Title
LU91348I2 (fr)	2007-09-18	Telbivudine et ses sels pharmaceutiquement acceptables
AR035711A1 (es)	2004-07-07	Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
JP2004513070A5 (fr)	2008-08-14
PL409123A1 (pl)	2014-12-22	Związki, ich zastosowanie i kompozycje do leczenia wirusowego zapalenia wątroby typu C
DE68926137D1 (de)	1996-05-09	Pyrimidin-Nukleoside
CY1112254T1 (el)	2015-12-09	Αρυλικοι φωσφοραμιδικοι εστερες νουκλεοζιτων και οι χρησεις τους ως αντι-ιικοι παραγοντες για την αντιμετωπιση του ιου της ηπατιτιδας c
MX9605809A (es)	1997-12-31	Nuevos esteres lipidicos de monofosfatos nucleosidos y su uso como medicamentos inmunosupresores.
IL200914A0 (en)	2010-05-17	2'-a-FLUORO-NUCLEOSIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING IT AND ITS USE IN THE MANUFACTURE OF MEDICAMENTS FOR TREATING HEPATITIS
ATE115958T1 (de)	1995-01-15	Nukleoside und nukleosid-analoge, pharmazeutische zusammensetzung und verfahren für die herstellung der bestandteile.
ATE74603T1 (de)	1992-04-15	Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
KR870006900A (ko)	1987-08-13	항바이러스 조성물
DE69031340D1 (de)	1997-10-02	3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
DE69929460D1 (de)	2006-04-06	Nukleoside mit anti-hepatitis b virus wirkung
BRPI0409088A (pt)	2006-04-11	composições farmacêuticas para administração intranasal de ácido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0]non-1(7)-en-2-il)alquil]-fosfÈnico e derivados e métodos de uso dos mesmos
HU901252D0 (en)	1990-05-28	Process for manufacturing of pharmaceutical compositions comprising purine derivatives
CY1117836T1 (el)	2017-05-17	Βητα-l-2'-δεοξυ-νουκλεοσιδια για την θεραπεια ηπατιτιδας β
ATE321561T1 (de)	2006-04-15	Azidoderivate von beta-l-2'-nukleosiden zur hiv- infektionsbehandlung
RU2001106651A (ru)	2003-04-20	Бета-l-2 - дезокси-нуклеотиды для лечения гепатита в
RU2001115094A (ru)	2003-03-10	Нуклеозиды, обладающие активностью против вируса гепатита в
KR890001560A (ko)	1989-03-27	항바이어러스 조성물